Back
Alnylam Pharmaceuticals, Inc. 10K Form
Sell
30
ALNY
Alnylam Pharmaceuticals, Inc.
Last Price:
$326.86
Seasonality Move:
-0.46%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
| 2023-11-02 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
| 2023-08-03 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
| 2023-05-04 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
| 2022-10-27 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
| 2022-07-28 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
Receive ALNY News And Ratings
See the #1 stock for the next 7 days that we like better than ALNY
ALNY Financial Statistics
Sales & Book Value
| Annual Sales: | $3.7B |
|---|---|
| Cash Flow: | $140.3M |
| Price / Cash Flow: | 91.4 |
| Annual Sales: | $5.96 |
| Price / Book: | 53.55 |
Profitability
| EPS (TTM): | 2.25710 |
|---|---|
| Net Income (TTM): | $313.7M |
| Gross Margin: | $3B |
| Return on Equity: | 107.73% |
| Return on Assets: | 6.83% |
Alnylam Pharmaceuticals, Inc. Earnings Forecast
Key Alnylam Pharmaceuticals, Inc. Financial Ratios
-
The Gross Profit Margin over the past 21 years for ALNY is 81.64%.
-
The Selling, General & Administrative Expenses for ALNY have been equal to 32.60% of Gross Profit Margin.
-
The Research & Development expenses have been 35.54% of Revenue.
-
The Interest Expense is 80.52% of Operating Income.
-
The Net Earning history of ALNY is 8.45% of Total Revenues.
-
Per Share Earnings over the last 24 years have been positive in 12 years.
Alnylam Pharmaceuticals, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ALNY |
| CUSIP: | 02043Q |
| Website: | alnylam.com |
Debt
| Debt-to-Equity Ratio: | 3.76 |
|---|---|
| Current Ratio: | 2.76 |
| Quick Ratio: | 2.51 |
Price-to-Earnings
| Trailing P/E Ratio: | 136.79 |
|---|---|
| Forward P/E Ratio: | 21.92 |
ALNY Technical Analysis vs Fundamental Analysis
Sell
30
Alnylam Pharmaceuticals, Inc. (ALNY)
is a Sell
Is Alnylam Pharmaceuticals, Inc. a Buy or a Sell?
-
Alnylam Pharmaceuticals, Inc. stock is rated a SellThe current Alnylam Pharmaceuticals, Inc. [ALNY] share price is $318.65. The Score for ALNY is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.